Information Provided By: 
Fly News Breaks for February 3, 2020
DHR
Feb 3, 2020 | 08:15 EDT
Needham analyst Stephen Unger raised his price target on Danaher to $187 and kept his Buy rating after its Q4 earnings beat and above-consensus Q1 guidance, with core revenue growth remaining "solid". The analyst adds that the company's FY20 EPS guidance of $4.80-$4.90 - below the expected $5.34 - do not reflect the 60c accretion from GE Biopharma business upon the deal's closing, though he warns that the outlook also does not reflect the potential headwinds from the recent China coronavirus outbreak.
News For DHR From the Last 2 Days
DHR
Apr 24, 2024 | 09:23 EDT
DHR
Apr 24, 2024 | 07:22 EDT
DHR
Apr 24, 2024 | 06:40 EDT
Baird raised the firm's price target on Danaher to $271 from $259 and keeps an Outperform rating on the shares. The firm said they reported 1Q results above expectations, helped by respiratory testing and bioprocessing upside. The company saw encouraging bioprocessing trends, with orders growing mid-single-digits, and noted normalization of large customer ordering patterns, with management expecting destocking to be largely complete by 2Q24-end.
DHR
Apr 24, 2024 | 06:32 EDT
DHR
Apr 24, 2024 | 05:28 EDT
Barclays raised the firm's price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company's orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.
